Table 1.

Endpoints

	Endpoint details
Primary endpoint	>25% improvement in perfusion defect size in adenosine-stress CMR from baseline to three months after udenafil treatment
Secondary endpoints	<25% improvement in perfusion defect size in adenosine-stress CMR from baseline to three months after udenafil treatment
	Decrement of frequency of chest pain
	Improvement of ST-depression in stress test
	Improvement of Duke score in stress test
	Improvement of QoL assessment by SF-36 questionnaire
	Improvement of sexual dysfunction assessment by BISF-W self-questionnaire
	Improvement of biomarkers for endothelial function

CMR; Cardiac magnetic resonance image, QoL; Quality of life.